Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS

ABSTRACT The aim of this study was to define the effects on antigen-presenting cells of the expression of HIV antigens from an attenuated poxvirus vector. We have analyzed the transcriptional changes in gene expression following infection of human immature monocyte-derived dendritic cells (DC) with recombinant modified vaccinia virus Ankara (MVA) expressing the genes encoding the gp120 and Gag-Pol-Nef antigens of HIV type 1 clade B (referred to as MVA-B) versus parental MVA infection. Using microarray technology and real-time reverse transcription-PCR, we demonstrated that the HIV proteins induced the expression of cytokines, cytokine receptors, chemokines, chemokine receptors, and molecules involved in antigen uptake and processing, including major histocompatibility complex (MHC) genes. Levels of mRNAs for interleukin-1, beta interferon, CCR8, and SCYA20 were higher after HIV antigen production. MVA-B infection also modulated the expression of antigen processing and presentation genes: the gene for MICA was upregulated, whereas those for HLA-DRA and HSPA5 were downregulated. Indeed, the increased expression of the gene for MICA, a glycoprotein related to major histocompatibility complex class I molecules, was shown to enhance the interaction between MVA-B-infected target cells and cytotoxic lymphocytes. The expression profiles of the genes for protein kinases such as JAK1 and IRAK2 were activated after HIV antigen expression. Several genes included in the JAK-STAT and mitogen-activated protein kinase signaling pathways were regulated after HIV antigen expression. Our findings provide the first gene signatures in DC of a candidate MVA-B vaccine expressing four HIV antigens and identified the biological roles of some of the regulatory genes, like that for MICA, which will help in the design of more effective MVA-derived vaccines.

[1]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[2]  P. Earl,et al.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. , 2009, Vaccine.

[3]  S. Akira,et al.  Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome , 2009, PLoS pathogens.

[4]  W. Cruikshank,et al.  Human Immunodeficiency Virus Type 1 gp120 Reprogramming of CD4+ T-Cell Migration Provides a Mechanism for Lymphadenopathy , 2009, Journal of Virology.

[5]  W. Kastenmuller,et al.  Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression , 2009, Journal of Virology.

[6]  P. Earl,et al.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. , 2008, The Journal of infectious diseases.

[7]  H. Rammensee,et al.  Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA1 , 2008, The Journal of Immunology.

[8]  M. Feinberg,et al.  Dendritic Cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo , 2008, BMC Immunology.

[9]  M. Krupa,et al.  The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. , 2008, Current gene therapy.

[10]  B. León,et al.  Monocyte migration to inflamed skin and lymph nodes is differentially controlled by L-selectin and PSGL-1. , 2008, Blood.

[11]  S. H. van der Burg,et al.  Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic , 2008, Proceedings of the National Academy of Sciences.

[12]  J. Heeney,et al.  Differential CD4 (cid:1) versus CD8 (cid:1) T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates (cid:1) † , 2022 .

[13]  S. Akira,et al.  Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses , 2007, Journal of Virology.

[14]  G. González-Aseguinolaza,et al.  Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. , 2007, The Journal of general virology.

[15]  T. Gallart,et al.  Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC , 2007, Journal of Virology.

[16]  G. Pantaleo,et al.  Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. , 2007, Vaccine.

[17]  G. Pantaleo,et al.  Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. , 2007, Vaccine.

[18]  Á. Zaballos,et al.  Human Gene Profiling in Response to the Active Protein Kinase, Interferon-induced Serine/threonine Protein Kinase (PKR), in Infected Cells , 2006, Journal of Biological Chemistry.

[19]  M. Carroll,et al.  Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial , 2006, Clinical Cancer Research.

[20]  S. Chisholm,et al.  Recognition of Vaccinia Virus-Infected Cells by Human Natural Killer Cells Depends on Natural Cytotoxicity Receptors , 2006, Journal of Virology.

[21]  M. Esteban,et al.  MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. , 2006, Microbes and infection.

[22]  A. Pascual-Montano,et al.  Host Response to the Attenuated Poxvirus Vector NYVAC: Upregulation of Apoptotic Genes and NF-κB-Responsive Genes in Infected HeLa Cells , 2006, Journal of Virology.

[23]  T. Gallart,et al.  CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Coligan,et al.  Cutting Edge: NKG2D Is a Costimulatory Receptor for Human Naive CD8+ T Cells , 2005, The Journal of Immunology.

[25]  J. Sirard,et al.  Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. , 2004, Vaccine.

[26]  K. Harshman,et al.  Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells , 2004, Journal of Virology.

[27]  Robert S Negrin,et al.  Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. , 2004, Blood.

[28]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[29]  G. McFadden,et al.  Poxviruses and immune evasion. , 2003, Annual review of immunology.

[30]  Mario Roederer,et al.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[31]  J. Carrascosa,et al.  Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells , 2003, Journal of Virology.

[32]  C. Staib,et al.  Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. , 2003, Current drug targets. Infectious disorders.

[33]  A. García-Sastre,et al.  Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes , 2003, Journal of Virology.

[34]  K. Harshman,et al.  Cellular Gene Expression Survey of Vaccinia Virus Infection of Human HeLa Cells , 2003, Journal of Virology.

[35]  T. Reinhart,et al.  Simian immunodeficiency virus dramatically alters expression of homeostatic chemokines and dendritic cell markers during infection in vivo. , 2003, Blood.

[36]  A. Moretta Natural killer cells and dendritic cells: rendezvous in abused tissues , 2002, Nature Reviews Immunology.

[37]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[38]  G. McFadden,et al.  Viral chemokine‐binding proteins , 2002, Journal of leukocyte biology.

[39]  Richard A Lempicki,et al.  HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Biassoni,et al.  Natural Killer Cells: A Mystery No More , 2002, Scandinavian journal of immunology.

[41]  R. Darnell,et al.  Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells , 2001, Nature Immunology.

[42]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[43]  D. Spehner,et al.  Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. , 2000, Virology.

[44]  J. Carrascosa,et al.  The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis. , 1999, Virology.

[45]  M. Plana,et al.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.

[46]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[47]  J. Ramírez,et al.  IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. , 1999, Journal of immunology.

[48]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[49]  P. Benias,et al.  A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. , 1998, Journal of immunological methods.

[50]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[51]  A. Alcamí,et al.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. , 1998, The Journal of general virology.

[52]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[53]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[54]  A. Alcamí,et al.  Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. , 1998, Journal of immunology.

[55]  B. Moss Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Esteban,et al.  Vaccinia virus A17L gene product is essential for an early step in virion morphogenesis , 1995, Journal of virology.

[57]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[58]  J. F. Rodríguez,et al.  Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  H. Stickl,et al.  [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin.

[60]  V. Hochstein-Mintzel,et al.  [Oral and nasal immunization with poxvirus vacciniae. IV. Studies of oral immunization in monkeys]. , 1973, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, praventive Medizin.

[61]  V. Hochstein-Mintzel,et al.  [Oral and nasal immunization with Poxvirus vacciniae. 3. Animal experiments]. , 1972, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, praventive Medizin.

[62]  V. Groh,et al.  Immunobiology of human NKG2D and its ligands. , 2006, Current topics in microbiology and immunology.

[63]  J. Coligan,et al.  NKG2D is a costimulatory receptor for human naive CD8+ T cells. , 2005, Journal of immunology.

[64]  Z. Rosenberg,et al.  Microbicides urgently needed: statement by IPM CEO, Zeda Rosenberg, on new AIDS statistics. Joint United Nations Programme on HIV/AIDS (UNAIDS) releases the 2004 AIDS epidemic update. , 2004 .

[65]  S. Riddell,et al.  Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. , 2001, Nature immunology.

[66]  S. Kunkel,et al.  Chemokines and innate immunity. , 2000, Reviews in immunogenetics.

[67]  B. Moss,et al.  Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. , 1996, Advances in experimental medicine and biology.

[68]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. , 1995, Cell.

[69]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[70]  H. Stickl,et al.  The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. , 1978 .